AMETEK posts record Q4 and 2025 results, accelerates M&A and medical device push in the U.S.

AMETEK finished 2025 with multiple company-first financials and a strong finish in the fourth quarter, as management highlighted robust top-line growth, expanding margins and unusually high cash conversion. Revenue in Q4 reached $2.0 billion, an increase compared with the prior-year quarter, while full-year sales exceeded $7 billion. Orders accelerated into year-end, producing a backlog that now supplies a visible revenue stream into 2026. Profitability advanced alongside sales: operating profit, EBITDA and diluted earnings per share all hit new highs, with core margins expanding versus the prior year. Free cash flow generation remained a standout, converting well above net income and underpinning the company’s ability to deploy capital. Management used that capacity to close several strategic deals in 2025 and announced another small medical-technology acquisition that broadens ophthalmic testing capabilities. Sector performance was mixed but constructive: electromechanical end markets delivered particularly strong organic expansion while electronic instruments began to re-accelerate after earlier softness. Geographic demand patterns showed strength in Asia, with China contributing meaningfully, and solid contributions from Europe and the U.S. Guidance for 2026 targets high single-digit overall sales growth and low- to mid-single-digit organic growth, with modest margin improvement and EPS growth in the mid-to-high single-digit range. The company reiterated a disciplined approach to capital allocation—prioritizing acquisitions but retaining capacity for buybacks and dividends—while forecasting elevated amortization from recent deals. Management acknowledged near-term margin dilution from lower-margin acquisitions but laid out a multi-year plan to lift those businesses toward AMETEK’s core profitability levels. With a large pipeline of M&A opportunities and a balance sheet positioned to act, the company expects to continue expanding its niche-market footprint while investing about $100 million incrementally into R&D, engineering and go-to-market initiatives in 2026. Overall, the results signal a transition from stabilization to selective growth, driven by portfolio optimization, product vitality and a focused acquisition cadence.